PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31685649-6 2019 Results showed that activation of PPARgamma by pioglitazone abolished the expression of somatic and affective nicotine withdrawal signs in rats and in (PPARgamma (+/+)) mice. Nicotine 110-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 34-43 31685649-0 2019 Activation of PPARgamma attenuates the expression of physical and affective nicotine withdrawal symptoms through mechanisms involving amygdala and hippocampus neurotransmission. Nicotine 76-84 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 31685649-3 2019 Preclinical and clinical data have shown that pioglitazone reduces alcohol and opioid self-administration, relapse to drug seeking and plays a role in emotional responses.Here, we investigated the behavioural effect of PPARgamma manipulation on nicotine withdrawal in male Wistar rats and in male mice with neuron-specific PPARgamma deletion (PPARgamma (-/-)) and their littermate wild type (PPARgamma (+/+)) controls. Nicotine 245-253 peroxisome proliferator-activated receptor gamma Rattus norvegicus 219-228 31685649-4 2019 Real-time quantitative RT-PCR and RNAscope in situ hybridization assays were used for assessing the levels of expression and cell-type localization of PPARgamma during nicotine withdrawal. Nicotine 168-176 peroxisome proliferator-activated receptor gamma Rattus norvegicus 151-160 31685649-11 2019 Our results demonstrate the implication of the neuronal PPARgamma in nicotine withdrawal and indicates that activation of PPARgamma may offer an interesting strategy for smoking cessation.SIGNIFICANCE STATEMENTSmoking cessation leads the occurrence of physical and affective withdrawal symptoms representing a major burden to quit tobacco use. Nicotine 69-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-65 31685649-11 2019 Our results demonstrate the implication of the neuronal PPARgamma in nicotine withdrawal and indicates that activation of PPARgamma may offer an interesting strategy for smoking cessation.SIGNIFICANCE STATEMENTSmoking cessation leads the occurrence of physical and affective withdrawal symptoms representing a major burden to quit tobacco use. Nicotine 69-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 122-131 31685649-12 2019 Here, we show that activation of PPARgamma prevents the expression of both somatic and affective signs of nicotine withdrawal. Nicotine 106-114 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-42 31685649-15 2019 Our results demonstrate the implication of neuronal PPARgamma in nicotine withdrawal and suggest that PPARgamma agonism may represent a promising treatment to aid smoking cessation. Nicotine 65-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-61 28381639-4 2017 Recently, perinatal nicotine injections in rats were reported to induce peroxisome proliferator-activated receptor gamma-dependent transgenerational transmission of asthma. Nicotine 20-28 peroxisome proliferator-activated receptor gamma Rattus norvegicus 72-120 26899624-2 2016 Mitochondrial abnormalities may contribute as the PPARgamma pathway is involved in structural and functional airway deficits after perinatal nicotine exposure. Nicotine 141-149 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-59 26899624-3 2016 We hypothesized perinatal nicotine exposure results in lung mitochondrial dysfunction that can be rescued by rosiglitazone (RGZ; PPARgamma receptor agonist). Nicotine 26-34 peroxisome proliferator-activated receptor gamma Rattus norvegicus 129-138 25661292-8 2015 The knock down of DNMT1 and MeCP2 abolished nicotine-mediated increases in DNMT1 and MeCP2 protein levels, and PPARgamma promoter methylation, restoring nicotine-induced down regulation of PPARgamma and upregulation of the myogenic protein, fibronectin. Nicotine 153-161 peroxisome proliferator-activated receptor gamma Rattus norvegicus 111-120 25659902-0 2015 PPAR-gamma agonist rosiglitazone reverses perinatal nicotine exposure-induced asthma in rat offspring. Nicotine 52-60 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 25659902-1 2015 In a rat model, downregulation of homeostatic mesenchymal peroxisome proliferator-activated receptor-gamma (PPAR-gamma) signaling following perinatal nicotine exposure contributes to offspring asthma, which can be effectively prevented by concomitant administration of PPAR-gamma agonist rosiglitazone (RGZ). Nicotine 150-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 108-118 25659902-1 2015 In a rat model, downregulation of homeostatic mesenchymal peroxisome proliferator-activated receptor-gamma (PPAR-gamma) signaling following perinatal nicotine exposure contributes to offspring asthma, which can be effectively prevented by concomitant administration of PPAR-gamma agonist rosiglitazone (RGZ). Nicotine 150-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 269-279 25659902-3 2015 We hypothesized that perinatal nicotine exposure-induced asthma would be reversed by PPAR-gamma agonist RGZ. Nicotine 31-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 85-95 25659902-10 2015 We conclude that perinatal nicotine exposure-induced functional and molecular alterations in upper and lower airways can be reversed by PPAR-gamma agonist RGZ, allowing an effective intervention even when started postnatally. Nicotine 27-35 peroxisome proliferator-activated receptor gamma Rattus norvegicus 136-146 25661292-0 2015 Perinatal nicotine exposure suppresses PPARgamma epigenetically in lung alveolar interstitial fibroblasts. Nicotine 10-18 peroxisome proliferator-activated receptor gamma Rattus norvegicus 39-48 25661292-2 2015 We have previously shown that perinatal nicotine exposure, by down-regulating PPARgamma expression, accentuates this property, culminating in myogenic pulmonary phenotype, though the underlying mechanisms remained incompletely understood. Nicotine 40-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 78-87 25661292-3 2015 We hypothesized that nicotine-induced PPARgamma down-regulation is mediated by PPARgamma promoter methylation, controlled by DNA methyltransferase 1 (DNMT1) and methyl CpG binding protein 2 (MeCP2), two known key regulators of DNA methylation. Nicotine 21-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 25661292-3 2015 We hypothesized that nicotine-induced PPARgamma down-regulation is mediated by PPARgamma promoter methylation, controlled by DNA methyltransferase 1 (DNMT1) and methyl CpG binding protein 2 (MeCP2), two known key regulators of DNA methylation. Nicotine 21-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-88 25661292-4 2015 Using cultured alveolar interstitial fibroblasts and an in vivo perinatal nicotine exposure rat model, we found that PPARgamma promoter methylation is strongly correlated with inhibition of PPARgamma expression in the presence of nicotine. Nicotine 74-82 peroxisome proliferator-activated receptor gamma Rattus norvegicus 117-126 25661292-4 2015 Using cultured alveolar interstitial fibroblasts and an in vivo perinatal nicotine exposure rat model, we found that PPARgamma promoter methylation is strongly correlated with inhibition of PPARgamma expression in the presence of nicotine. Nicotine 74-82 peroxisome proliferator-activated receptor gamma Rattus norvegicus 190-199 25661292-4 2015 Using cultured alveolar interstitial fibroblasts and an in vivo perinatal nicotine exposure rat model, we found that PPARgamma promoter methylation is strongly correlated with inhibition of PPARgamma expression in the presence of nicotine. Nicotine 230-238 peroxisome proliferator-activated receptor gamma Rattus norvegicus 117-126 25661292-4 2015 Using cultured alveolar interstitial fibroblasts and an in vivo perinatal nicotine exposure rat model, we found that PPARgamma promoter methylation is strongly correlated with inhibition of PPARgamma expression in the presence of nicotine. Nicotine 230-238 peroxisome proliferator-activated receptor gamma Rattus norvegicus 190-199 25661292-5 2015 Methylation inhibitor 5-aza-2"-deoxycytidine restored the nicotine-induced down-regulation of PPARgamma expression and the activation of its downstream myogenic marker fibronectin. Nicotine 58-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-103 25661292-6 2015 With nicotine exposure, a specific region of PPARgamma promoter was significantly enriched with antibodies against chromatin repressive markers H3K9me3 and H3K27me3, dose-dependently. Nicotine 5-13 peroxisome proliferator-activated receptor gamma Rattus norvegicus 45-54 25661292-8 2015 The knock down of DNMT1 and MeCP2 abolished nicotine-mediated increases in DNMT1 and MeCP2 protein levels, and PPARgamma promoter methylation, restoring nicotine-induced down regulation of PPARgamma and upregulation of the myogenic protein, fibronectin. Nicotine 44-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 189-198 25661292-8 2015 The knock down of DNMT1 and MeCP2 abolished nicotine-mediated increases in DNMT1 and MeCP2 protein levels, and PPARgamma promoter methylation, restoring nicotine-induced down regulation of PPARgamma and upregulation of the myogenic protein, fibronectin. Nicotine 153-161 peroxisome proliferator-activated receptor gamma Rattus norvegicus 189-198 25661292-9 2015 The nicotine-induced alterations in DNA methylation modulators DNMT1 and MeCP2, PPARgamma promoter methylation, and its down-stream targets, were also validated in perinatally nicotine exposed rat lung tissue. Nicotine 4-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-89 25661292-9 2015 The nicotine-induced alterations in DNA methylation modulators DNMT1 and MeCP2, PPARgamma promoter methylation, and its down-stream targets, were also validated in perinatally nicotine exposed rat lung tissue. Nicotine 176-184 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-89 25661292-10 2015 These data provide novel mechanistic insights into nicotine-induced epigenetic silencing of PPARgamma that could be exploited to design novel targeted molecular interventions against the smoke exposed lung injury in general and perinatal nicotine exposure induced lung damage in particular. Nicotine 51-59 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-101 25661292-10 2015 These data provide novel mechanistic insights into nicotine-induced epigenetic silencing of PPARgamma that could be exploited to design novel targeted molecular interventions against the smoke exposed lung injury in general and perinatal nicotine exposure induced lung damage in particular. Nicotine 238-246 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-101 23379695-5 2013 These alterations were blocked by co-administration of the peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, implicating downregulation of this receptor in the nicotine effects. Nicotine 183-191 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-107 23149826-0 2013 Possible involvement of PPARgamma-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Nicotine 110-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-33 23149826-8 2013 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Nicotine 344-352 peroxisome proliferator-activated receptor gamma Rattus norvegicus 40-88 23149826-8 2013 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Nicotine 344-352 peroxisome proliferator-activated receptor gamma Rattus norvegicus 90-99 23149826-11 2013 Rosuvastatin prevents nicotine-induced vascular endothelial abnormalities by activating PPARgamma and endothelial NOS signaling pathways. Nicotine 22-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 88-97 21355041-0 2011 PPARgamma agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring. Nicotine 51-59 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 23106849-1 2012 BACKGROUND: By altering specific developmental signaling pathways that are necessary for fetal lung development, perinatal nicotine exposure affects lung growth and differentiation, resulting in the offsprings" predisposition to childhood asthma; peroxisome proliferator-activated receptor gamma (PPARgamma) agonists can inhibit this effect. Nicotine 123-131 peroxisome proliferator-activated receptor gamma Rattus norvegicus 247-295 23106849-1 2012 BACKGROUND: By altering specific developmental signaling pathways that are necessary for fetal lung development, perinatal nicotine exposure affects lung growth and differentiation, resulting in the offsprings" predisposition to childhood asthma; peroxisome proliferator-activated receptor gamma (PPARgamma) agonists can inhibit this effect. Nicotine 123-131 peroxisome proliferator-activated receptor gamma Rattus norvegicus 297-306 23106849-8 2012 All of the nicotine-induced changes in the lung and gonad DNA methylation and histone 3 and 4 acetylation were normalized by the PPARgamma agonist rosiglitazone except for the histone 4 acetylation in the lung. Nicotine 11-19 peroxisome proliferator-activated receptor gamma Rattus norvegicus 129-138 23002101-1 2013 Recently, we have suggested that down-regulation of homeostatic mesenchymal peroxisome proliferator-activated receptor gamma signaling after in utero nicotine exposure might contribute to asthma. Nicotine 150-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 76-124 21355041-3 2011 Recently, we suggested that downregulation of homeostatic mesenchymal peroxisome proliferator-activated receptor-gamma (PPARgamma) signaling following in utero nicotine exposure might contribute to chronic lung diseases such as asthma. Nicotine 160-168 peroxisome proliferator-activated receptor gamma Rattus norvegicus 120-129 18687784-6 2008 The prenatal nicotine exposure also led to an increase in epididymal white adipose tissue weight at weaning (postnatal d 21), and marked hypertrophy of adipocytes, with increased gene expression of proadipogenic transcription factors such as CAAT-enhancer-binding protein-alpha, peroxisome proliferator activated receptor-gamma, and sterol regulatory element binding protein-1C. Nicotine 13-21 peroxisome proliferator-activated receptor gamma Rattus norvegicus 271-327 17215434-9 2007 More importantly, concomitant administration of PPAR-gamma agonists can effectively attenuate many of the effects of in utero exposure to nicotine on ATII cells. Nicotine 138-146 peroxisome proliferator-activated receptor gamma Rattus norvegicus 48-58 35600600-5 2022 Our data revealed that perinatal exposure to nicotine leads to alterations in the profiles of sperm-borne RNAs, including mRNAs and small RNAs, and that rosiglitazone, a PPARgamma agonist, can attenuate the effect of nicotine and reverse the sperm-borne RNA profiles of F1 male rats to close to placebo control levels. Nicotine 217-225 peroxisome proliferator-activated receptor gamma Rattus norvegicus 170-179